Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Deals

Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology

Fineline Cube Jun 9, 2025

China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot...

Company Deals

CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine

Fineline Cube Jun 9, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) and Hong Kong-based Qianlong International Holdings Ltd....

Company Drug

AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment

Fineline Cube Jun 9, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...

Company Drug

Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD

Fineline Cube Jun 9, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,...

Company Deals

Lifetech Scientific Plans RMB 150 Million Investment in AffectOR MedTech

Fineline Cube Jun 9, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced plans to invest RMB 150 million (USD 21...

Company Deals

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

Fineline Cube Jun 9, 2025

Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug...

Company Drug

NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial

Fineline Cube Jun 9, 2025

China-based NeoCura Bio-Medical Technology Co., Ltd. announced that it has received approval from the National...

Company Drug

YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101

Fineline Cube Jun 9, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...

Company Deals

Kindstar Global Partners with Biostate AI to Advance Precision Medicine

Fineline Cube Jun 9, 2025

China-based Kindstar Global (HKG: 9960) announced the establishment of a joint venture (JV) with US-headquartered...

Company Medical Device

Genesis MedTech Wins NMPA Approval for Locally Developed Thrombus Aspiration Catheter

Fineline Cube Jun 9, 2025

Singapore-based Genesis MedTech announced that it has received marketing approval from China’s National Medical Products...

Company Deals

Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China

Fineline Cube Jun 6, 2025

China’s Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA...

Company Drug

HELP Therapeutics’ iPSC-Derived Cardiomyocyte Therapy Enters US Clinical Trials

Fineline Cube Jun 6, 2025

Nanjing-based HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, announced that its innovative induced...

Company Deals

Lancet Robotics Secures Series A+ Funding for Surgical Robot Development

Fineline Cube Jun 6, 2025

Shenzhen-based Lancet Robotics, a developer of orthopedic joint replacement surgical robots, has reportedly secured “tens...

Legal / IP

Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio

Fineline Cube Jun 6, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key...

Company Deals Drug

Bayer’s Vividion Gains Global Rights to WRN Inhibitor VVD-214

Fineline Cube Jun 6, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its wholly owned subsidiary Vividion Therapeutics,...

Company Deals

Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress

Fineline Cube Jun 6, 2025

China-based Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotech company focusing on oncology and autoimmune...

Company Medical Device

Acotec Scientific Gains NMPA Approval for AcoArt Verbena Vertebral Balloon

Fineline Cube Jun 6, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has received marketing approval from China’s National Medical...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors

Fineline Cube Jun 6, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

Qure Biotechnology Secures RMB 100 Million Series C1 Financing

Fineline Cube Jun 6, 2025

China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round...

Company Drug

Lianhuan Pharma Gains NMPA Approval for No-Spa Generic

Fineline Cube Jun 6, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...

Posts pagination

1 … 161 162 163 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.